Merck KGaA Names Head of Global Oncology

From DCAT Value Chain Insights (VCI)

By People On The Move posted 04-19-2016 14:29


Merck KGaA has appointed Maya Martinez-Davis as global head of its oncology franchise for its biopharma business. She will report to Rehan Verjee, chief marketing and strategy officer of the healthcare business sector of Merck KGaA. She will be based in Billerica, Massachusetts.

In this role, she will be responsible for defining integrated global oncology strategies and the delivery of therapeutic launches, starting with avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck KGaA, and currently managed under a strategic alliance with Pfizer. The first potential commercial launch for avelumab is expected in 2017.

Prior to joining Merck KGaA, Martinez-Davis was a senior executive with Pfizer for more than a decade, delivering on therapeutic area portfolio strategies, in-market growth strategies, and major launches. Prior to her tenure with Pfizer, she held senior-level and director-level positions with Aventis Pharma in oncology.

Martinez-Davis assumes the role of her predecessor, Andrew Schiermeier.

Source: Merck KGaA


Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT). 

Learn more and sign up to receive a complimentary subscription